These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 10964871)

  • 21. Are paroxetine, fluoxetine, and sertraline equally effective for depression?
    Straton JB; Cronholm P
    J Fam Pract; 2002 Mar; 51(3):285. PubMed ID: 11978244
    [No Abstract]   [Full Text] [Related]  

  • 22. Venlafaxine extended-release: a review of its use in the management of major depression.
    Wellington K; Perry CM
    CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study.
    Montgomery SA; Kennedy SH; Burrows GD; Lejoyeux M; Hindmarch I
    Int Clin Psychopharmacol; 2004 Sep; 19(5):271-80. PubMed ID: 15289700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of SNS activation on SSRI-induced sexual side effects differ by SSRI.
    Ahrold TK; Meston CM
    J Sex Marital Ther; 2009; 35(4):311-9. PubMed ID: 19466669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction of serotonin re-uptake inhibitors with perhexiline.
    Alderman CP; Hundertmark JD; Soetratma TW
    Aust N Z J Psychiatry; 1997 Aug; 31(4):601-3. PubMed ID: 9272272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heterogeneity of SSRI response.
    Salzman C
    Harv Rev Psychiatry; 1996; 4(4):215-7. PubMed ID: 9384996
    [No Abstract]   [Full Text] [Related]  

  • 27. Magnetization transfer of fluoxetine in the human brain using fluorine magnetic resonance spectroscopy.
    Strauss WL; Dager SR
    Biol Psychiatry; 2001 May; 49(9):798-802. PubMed ID: 11331088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Remission of SSRI-induced akathisia after switch to nefazodone.
    Chelben J; Strous RD; Lustig M; Baruch Y
    J Clin Psychiatry; 2001 Jul; 62(7):570-1. PubMed ID: 11488371
    [No Abstract]   [Full Text] [Related]  

  • 29. Hormonal markers of stress response following interruption of selective serotonin reuptake inhibitor treatment.
    Michelson D; Amsterdam J; Apter J; Fava M; Londborg P; Tamura R; Pagh L
    Psychoneuroendocrinology; 2000 Feb; 25(2):169-77. PubMed ID: 10674280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.
    Shelton C; Entsuah R; Padmanabhan SK; Vinall PE
    Int Clin Psychopharmacol; 2005 Jul; 20(4):233-8. PubMed ID: 15933485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder.
    Bakish D; Cavazzoni P; Chudzik J; Ravindran A; Hrdina PD
    Biol Psychiatry; 1997 Jan; 41(2):184-90. PubMed ID: 9018388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Depression: making the diagnosis and using SSRIs in the older patient.
    Reynolds CF
    Geriatrics; 1996 Oct; 51(10):28-34. PubMed ID: 8863755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study.
    Diav-Citrin O; Shechtman S; Weinbaum D; Wajnberg R; Avgil M; Di Gianantonio E; Clementi M; Weber-Schoendorfer C; Schaefer C; Ornoy A
    Br J Clin Pharmacol; 2008 Nov; 66(5):695-705. PubMed ID: 18754846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective serotonin reuptake inhibitor usage patterns as risk factors for hospitalization.
    Sheffield RE; Lo Sasso AT; Young CH; Way K
    Adm Policy Ment Health; 2002 Nov; 30(2):121-39. PubMed ID: 12680617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tardive dyskinesia associated with fluoxetine.
    Dubovsky SL; Thomas M
    Psychiatr Serv; 1996 Sep; 47(9):991-3. PubMed ID: 8875667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder.
    Ballenger JC; Wheadon DE; Steiner M; Bushnell W; Gergel IP
    Am J Psychiatry; 1998 Jan; 155(1):36-42. PubMed ID: 9433336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder.
    Chouinard G; Saxena B; Bélanger MC; Ravindran A; Bakish D; Beauclair L; Morris P; Vasavan Nair NP; Manchanda R; Reesal R; Remick R; O'Neill MC
    J Affect Disord; 1999 Jul; 54(1-2):39-48. PubMed ID: 10403145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical practice guidelines for depression in young people.
    Jureidini JN; Tonkin AL
    Med J Aust; 2003 Mar; 178(6):300; author reply 300-2. PubMed ID: 12633493
    [No Abstract]   [Full Text] [Related]  

  • 39. Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study.
    Emslie GJ; Heiligenstein JH; Hoog SL; Wagner KD; Findling RL; McCracken JT; Nilsson ME; Jacobson JG
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1397-405. PubMed ID: 15502599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Duration of therapy and health care costs of fluoxetine, paroxetine, and sertraline in 6 health plans.
    Polsky D; Onesirosan P; Bauer MS; Glick HA
    J Clin Psychiatry; 2002 Feb; 63(2):156-64. PubMed ID: 11874218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.